Incretin-based therapies and sodium-glucose cotransporter 2 (SGLT-2) inhibitors are now being worked on as novel classes of glucose-lowering drugs used in the management of T2DM and are proving to be playing a simultaneous role in improving liver health (224) (Table 3). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.